⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VCYT News
Veracyte, Inc.
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
businesswire.com
VCYT
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
businesswire.com
VCYT
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
businesswire.com
VCYT
Veracyte to Participate in Upcoming Investor Conferences
businesswire.com
VCYT
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
businesswire.com
VCYT
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
globenewswire.com
HTFL
CTKB
VCYT
BFLY
Form 8-K
sec.gov
VCYT
Veracyte Announces First Quarter 2026 Financial Results
businesswire.com
VCYT
Labbit Goes All-In on LIMS Platform, Retires Semaphore Solutions Brand
prnewswire.com
VCYT
BILI
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
businesswire.com
VCYT